Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival

Journal of the American College of Cardiology

Volumn 40, Issue 9, 2002, Pages 1609-1614

  Mehra, Mandeep R ^a   Uber, Patricia A ^a   Vivekananthan, Krishnamoorthy ^a   Solis, Sergio ^a   Scott, Robert L ^a   Park, Myung H ^a   Milani, Richard V ^a   Lavie, Carl J ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMODYNAMIC MONITORING; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; MALE; MYOSITIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SCORING SYSTEM; SEPTIC SHOCK;

ADOLESCENT; ADULT; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES; SIMVASTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037032264     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02340-9     Document Type: Article

References (19)

1. Ballantyne CM. Statins after cardiac transplantation: Which statin, what dose, and how low should we go? J Heart Lung Transplant 2000;19:515-7.
2. Rosenson R, Tangney C. Antiatherosclerotic properties of statins. JAMA 1998;279:1643-50.
3. Kobashigawa J, Katznelson S, Laks H, et al. Effect of pravastatin in outcomes after cardiac transplantation. N Engl J Med 1995;333: 621-7.
4. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs. simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:529-37.
5. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation - A four year randomised trial. Circulation 1997;96:1398-402.
6. Mehra MR, Ventura HO, Chambers R, et al. Predictive model to assess risk for cardiac allograft vasculopathy: An intravascular ultra-sound study. J Am Coll Cardiol 1995;26:1537-44.
7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
8. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143-8.
9. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3- methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
10. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-71.
11. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals (see comments). Nat Med 2000;6:1004-10.
12. Jialai I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
13. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
14. Holschermann H, Hilgendorff A, Kemkes-Matthes B, et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000;15;69:1830-6.
15. Katznelson S, Wang XM, Chia D, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998;17:335-40.
16. Weis M, Pehlivanli S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001;38:814-8.
17. Vanhaecke J, Cleemput J, Van Lierde J, Daenen W, De Geest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994;58: 42-5
18. Arnadottir M, Eriksson LO, Germershausen JI, Thysell H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: Double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994; 68:57-62.
19. Ishigami M, Honda T, Takasaki W, et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 2001;29:282-8.